Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists hunt for biomarkers to unlock rare eye disease treatments

NCT ID NCT07063719

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study aims to find biological markers (biomarkers) in blood, tears, and eye cells from 110 adults with seven rare eye diseases. Researchers will compare these markers between patients and healthy controls to see if they differ and if they relate to disease symptoms. The goal is to better understand these diseases and support future drug development.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify key biological markers that help design and test new treatments for rare eye diseases.
What could go wrong
This is an observational study, not a treatment trial. It is early-stage research, and the findings may not directly lead to new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patient group: * Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study) * Willingness and ability to read and understand the informed consent. * Diagnosis (including genotype, if needed) of REDs. * Affiliation with a social security scheme or beneficiary of such a scheme. RED 1 - AAK Diagnosis criteria * Compatible slit lamp examination (iris/pupillary abnormalities, with or without corneal opacification, vascularization, cataract, glaucoma). with or without: * Foveal hypoplasia and optic disc malformations as detected through fundus examination or OCT tomography * Compatible anterior segment OCT or high-frequency ultrasound biomicroscopy (UBM) * Positive genetic testing RED 2 - NK Diagnosis criteria * Compatible history and slit lamp findings of one of the three stages of the Mackie classification (I - punctate keratopathy; II - persistent epithelial defect; III - stromal involvement) * Reduced/absent corneal sensitivity * Exclusion of infectious or toxic etiologies with or without: * confocal microscopy findings RED 3 - LSCD Diagnosis criteria * Compatible history and slit lamp examination (e.g. corneal conjunctivalization with persistent epithelial defects, loss of limbal anatomy or irregular staining with fluorescein) with or without: * confocal microscopy findings RED 4 - OCP Diagnosis criteria * Compatible slit lamp examination * Exclusion of infectious or toxic etiologies with or without: * conjunctival /oral biopsy with characteristic mucous pemphigoid findings RED 5 - OC GVHD Diagnosis criteria • Compatible history and slit lamp examination consistent with one of 4 grades of ocular GVHD (1 - conjunctival hyperemia, 2 - fibrovascular changes \<25% of palpebral conjunctiva, 3 - fibrovascular changes \>25%, 4 - \>75% or cicatricial entropion) RED 6 - EEC Diagnosis criteria * Compatible slit lamp examination * Compatible systemic findings with or without: * Positive genetic testing RED 7- CNV Diagnosis criteria * Compatible slit lamp examination of corneal stromal neovascularization (1-4 quadrants) * Exclusion of infectious or toxic etiologies with or without: * confocal microscopy findings Control group: * Women and men with age equal or higher than 18 years (patients planning to conceive may be included in the study). * Willingness and ability to read and understand the informed consent. * Non-diagnosis of REDs. * Affiliation with a social security scheme of beneficiary of such a scheme. Exclusion Criteria: Patient group: * Pregnancy, breastfeeding (in case any stress was caused to the woman by the biological sampling). * Descemetocele/impending corneal perforation. * Recent (less than 3 months) ocular surgery. * Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology. * Persons subject to a legal protection measure (under guardianship, curatorship or safeguard of justice) Control group: * Pregnancy, breastfeeding. * Active ocular infection. * Descemetocele/impending corneal perforation. * Recent (less than 3 months) ocular surgery. * Recent (less than 1 month) change in topical medications type and frequency of the ocular pathology. * Persons subject to a legal protection measure. (under guardianship, curatorship or safeguard of justice)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aniridia-associated keratopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Universitaire Cochin, APHP

    RECRUITING

    Paris, France

  • Hôpital Universitaire Necker Enfants malades, APHP

    NOT_YET_RECRUITING

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.